Should be an interesting week leading up to the earnings call. I expect NPS will report that GATTEX is ahead of the curve on patients on the drug, SENSIPAR is continuing to return terrific royalties and will soon go 100% to NPS and they are around the corner for BLA on NATPARA. We are a $20+ stock and only going up further as these things play out, particularly if they can start to discuss expanded markets for these drugs and new products in the pipeline.
They need to fix Natpara problems ASAP. Would like to hear that they were resolved. Also would like to know about calcilytics program. In one of the recent presentations they mentioned a possibility to acquire a new product. If the company is going to establish a sale force they could promote more than one or two products. Would be nice if they mention it again.
I think NATPARA is approved ,used and sold in the EU. Eventually whatever problem
may exist will be resolved, then BOOM 25-30 for openers. 3 years hence I see 30-50. Massive buy ins may occur, Short will wither as they look for shares to buy. As of now there are over 10.2 million SHORT shares which need to be covered.